GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Class III Regenerative Treatments?

Class III regenerative treatments fall within Japan’s lowest-risk regulatory category for regenerative medicine — procedures that are neither Class I nor Class II under the safety law En. Japan had 4,272 Class III treatment plans on file as of 30 June 2026 — about 63% of 6,743 treatment plans in total, compared with 8 Class I and 2,463 Class II plans 001590173.pdf. The label describes regulatory risk and procedural requirements, not whether a treatment works En.

A clinic’s claim that its offer is Class III is not enough: verify the submitted plan and its stated class. The law requires advance submission and committee review, but filing is not product approval, proof of benefit, or a guarantee of personal safety En.

What Are Class III Regenerative Treatments?

This article is general information about the Japanese regulatory system, not personal medical advice.

The short answer

The class describes regulatory risk, not the disease treated or the likelihood of recovery. The official overview uses somatic-cell procedures as examples of Class III; it does not establish that every treatment marketed as a stem-cell treatment belongs in that class 000154889.pdf.

A Class III treatment plan is a regulatory record, not an approved regenerative medical product. Product claims must be checked separately against PMDA’s approved-product information and review reports 0003.

Class III versus Class I and Class II

The table compares the broad categories and review routes; it cannot classify an individual offer. Each class has procedural requirements, not an effectiveness rating 000154889.pdf.

Class Risk level in law What it generally covers Review route
Class I Highest risk Procedures with the greatest uncertainty or potential for serious effects even with careful practice, including work involving induced pluripotent stem cells, embryonic stem cells, and similar high-risk technologies Review by a specially certified committee, with a restricted provision period after submission during which the health ministry can order changes
Class II Middle risk Procedures where careful practice still leaves real risk to life or health, including many somatic stem-cell uses Review by a specially certified committee, with plan submission
Class III Lower risk within this law Procedures that fit neither of the first two groups; the official overview gives somatic-cell procedures as examples Review by a standard certified committee, with plan submission

Lower risk here means a lower category in the regulatory framework, not a measured comparison of adverse-event rates En. The procedure can still carry risks, and the class does not establish clinical benefit.

What falls into Class III

The law defines Class III by exclusion: it covers regenerative medicine technology that is not Class I or Class II technology under the applicable Ministry of Health, Labour and Welfare rules. The factors below help explain classification, but are not a substitute for those rules or the actual plan En.

Cell type

The official background overview gives embryonic and induced pluripotent stem cells as examples in Class I, somatic stem cells in Class II, and somatic-cell procedures in Class III. These examples explain the broad distinction; they are not a current ruling on every intervention using those cells 000154889.pdf.

Processing

Ask whether cells are cultured or otherwise processed, whether genes are introduced, and what manufacturing and quality controls apply. The law addresses processed cells and requires information about manufacturing and quality control in the provision plan. The word cultured alone does not establish the class, and processing intensity is not a stand-alone classification test En.

Donor and use

Ask where the cells come from and what they are intended to do. Using the patient’s own cells does not by itself establish Class III status. Homologous use means using cells for the same basic function; the term alone is not a complete Japanese classification rule. The official overview calls for considering cells and administration methods together 000154889.pdf. The difference between using your own cells and donor cells is explained in this overview of autologous versus allogeneic stem cells.

A brochure name such as stem cells does not fix the class. Compare seven practical details across the documents: stated class, cell source, processing method, dose or dosing method, route, schedule, and intended recipients. This is a document-comparison checklist, not a seven-part legal test; classification follows the applicable rules, not merely what a provider writes on a form En.

What Class III does not mean

Readers usually ask whether Class III means approved, tested, or safe. It helps to keep four ideas apart:

Filed plan

A filed provision plan means a clinic submitted documents under the safety law Index. Those documents describe the provider, the treatment, the risk class, the reviewing committee, and the consent materials 0000186471. The plan went through committee review and carries reporting duties. None of that is a finding that the treatment works. How those filing and compliance duties work in practice is summarized in this explanation of registration and compliance for regenerative medicine in Japan.

Product approval

Product approval follows the separate Pharmaceuticals and Medical Devices Act route, with review work by the Pharmaceuticals and Medical Devices Agency. Check the named product’s review report, approved indication, dosage, administration method, and any approval conditions. An approval for one product or use does not approve a different clinic procedure or guarantee an individual outcome 0003.

Trial registration

Trial registration means a study is listed with information about its methods, eligibility, and endpoints. A record may also include its status and results. Registration alone is not evidence that the treatment works; read the actual results and assess their quality Jrct.mhlw.go.jp.

Facility record

A clinic license or a processing-facility record only shows who may provide care or handle cells 0000186471. It does not approve every treatment offered there.

Ask the clinic which document supports its claim — a provision plan, a product approval, or a research registration — and match the answer to the relevant official record.

How a Class III plan is reviewed and listed

If you want to verify a clinic’s wording, this is the route its plan should have taken. A clinic cannot call itself Class III and start treating patients on that word alone. A certified regenerative medicine committee must review the plan before submission En. After that, the clinic must follow the submission, reporting, and follow-up requirements Index. The usual sequence from consultation through follow-up is described in this outline of the stem cell treatment process in Japan.

Classes I and II require specially certified committees. For Class I, Articles 8 and 9 describe a 90-day review and provision-restriction period after submission, with provisions allowing the ministry to shorten or extend it. It is not an absolute 90-day maximum. Class III does not use that Class I waiting-period mechanism, but committee review and advance submission are still required En.

The ministry publishes provider and plan information through its online regenerative-medicine system, often called e-Saiseiiryo Saiseiiryo.mhlw.go.jp. Anyone can browse the public lists, which are split by risk class 0000186471. The published record shows the institution, treatment name and class, reviewing committee, explanation and consent documents, and any administrative orders 0000186471. For research plans under the same law, the public record runs through the Japan Registry of Clinical Trials Jrct.mhlw.go.jp.

The linked public plan lists are in Japanese. Keep the institution’s Japanese name and plan number when searching; an English brochure name may not match the registry entry. If you cannot read the documents, obtain a reliable translation of the treatment description, consent form, and committee information before deciding 0000186471.

How many Class III plans exist

A ministry snapshot as of 30 June 2026 records 6,743 treatment plans on file — 8 Class I, 2,463 Class II, and 4,272 Class III — plus 85 research plans counted separately 001590173.pdf. Those figures count plans only, not unique clinics, patients, approved products, or proven treatments. They are not a live availability list.

By share, Class III made up about 63.4% of treatment plans, Class II about 36.5%, and Class I about 0.1%, calculated from the ministry’s 30 June 2026 counts 001590173.pdf. Those shares describe filing distribution under one law. They say nothing about success rates or who a treatment suits.

Approved regenerative medical products belong to a separate regulatory route. Consult PMDA’s product-specific information rather than treating a provision-plan count as an approval count or a list of available clinic treatments 0003.

Plan counts and product approvals measure different things. Dividing one by the other would not produce a valid approval rate or a personal chance of benefit 001590173.pdf 0003.

Class III risks do not disappear

Lowest-risk does not mean risk-free. The law still requires safety measures and informed consent for Class III; classification is not a patient-specific safety assessment En. General safety questions are also discussed in this overview of whether stem cell therapy is safe in Japan.

Ask about risks at each step: bleeding, infection, and any anesthesia risks during collection; contamination, mix-ups, and cell-quality problems during processing; and local injury, infection, or systemic reactions during administration. Which risks apply depends on the exact procedure and route. Ask how delayed problems will be detected and managed after you return home; the class label supplies neither an adverse-event rate nor a follow-up plan.

After approval, the package insert still lists the warnings, contraindications, and adverse reactions. A filed Class III plan instead has consent documents, which should describe the proposed procedure, eligibility, alternatives, risks, costs, and follow-up 0000186471. Read those papers for the exact offer, and do not assume a low-risk label means a simple or painless experience. Eligibility and contraindications are discussed further in this guide to indications and contraindications for stem cell therapy in Japan.

How to check a Class III claim

If a brochure says Class III, the plan number and institution name matter more than the headline. Practical points on vetting a provider are listed in this guide to how to choose a stem cell hospital in Japan.

Get the complete plan number plus the institution’s official Japanese name, treatment name, and location. Then confirm which risk class the filed documents state, which certified committee reviewed the plan, and whether the papers you received match the current filing — including any changes to cells, dose, route, sessions, eligibility, or follow-up 0000186471 Saiseiiryo.mhlw.go.jp.

The quote, consent form, and plan should agree on cells, processing, dose or dosing method, route, session schedule, condition, and eligibility group. Check as well where the cells are processed — inside the clinic or at an outside facility such as a cell processing center — what release testing is used, who assesses you, who performs the procedure, who manages complications, and what follow-up is included after you return home 0000186471.

When a clinic says its treatment is approved, get the exact product name, non-proprietary name, applicant, indication, and approval number, then look for that product in the approved-product list and its review report 0003. A filed plan should appear in the public plan lists by risk class under the same provider and treatment name 0000186471; research should appear in the clinical research registry Jrct.mhlw.go.jp. Read the protocol, eligibility, recruitment status, and any posted results there. A registration alone does not prove benefit Jrct.mhlw.go.jp.

If the class, product, indication, or route in the brochure does not match the official record, ask the clinic in writing to explain the difference before you pay anything.

For a practical document check, place the quote and consent form beside the plan. If a quote describes an intravenous infusion but the plan describes a local injection, treat that as an unresolved mismatch, not as an interchangeable route. Ask which current plan covers the exact proposed procedure. This hypothetical comparison illustrates a document check; it is not a report of a patient case.

Unsure whether a Class III offer is a filed plan, an approved product, or a trial?

Send the treatment name and plan or approval number, and confirm what the official record shows before you decide.

Ask about this treatment

Questions to ask about a Class III offer

  • What is the exact treatment name, plan number, risk class, and reviewing committee in the filed documents?
  • Is this a filed provision plan, an approved product, or a clinical trial, and what is the approval or registration number?
  • Which diagnosis, stage, and eligibility criteria does the filed plan cover, and how does my case fit?
  • What is the cell source, processing method including culture, dose or dosing method, route, and number of sessions?
  • Where are cells processed, under which oversight route, and what release tests are used?
  • Which certified committee reviewed this plan, and can I see the explanation and consent documents?
  • What are the known risks, what alternatives exist, and who manages complications after I return home?
  • What does the quoted price include, including collection, processing, testing, administration, follow-up, and travel-related care?

Limits of the Class III label

The Class III label has clear limits for your decision En. It will not tell you whether a treatment will help you in particular, whether it beats standard care, what it costs, whether insurance covers it, or whether a clinic offers it today. Nor can it rank plans: two plans can share the same class yet differ in cells, processing, dose, route, condition, evidence, and follow-up.

The 6,743-plan total as of 30 June 2026 cannot answer personal questions either 001590173.pdf. It records filings under one law at one date, not outcomes. It says nothing about how any one person will respond, how good any one clinic is, or how strong the evidence is for any one disease.

To judge a benefit claim, look for human evidence matching the disease and stage, cell type, processing, dose, and route. Check the trial phase, population, sample size, comparison group, prespecified endpoints, follow-up, and adverse events. Where benefits are reported, distinguish absolute from relative effects. A registry entry can help locate a study, but cannot replace its results; PubMed indexing alone does not establish study quality Jrct.mhlw.go.jp.

What to remember about Class III

Class III means the lowest-risk category under Japan’s safety law — neither Class I nor Class II — not product approval or proof of benefit En. Japan had 4,272 Class III plans out of 6,743 treatment filings as of 30 June 2026; these are plan counts, not treatment outcomes 001590173.pdf.

For any offer described as Class III, check the exact plan, institution, class, committee, cells, processing, indication, and follow-up in the filed documents 0000186471. Use the approved-product list for product claims and the trial registry for research claims 0003 Jrct.mhlw.go.jp. A filed plan stays a regulatory record with ongoing duties; it never promises the treatment will work for you.

Sources

These sources concern Japan. The plan figures are a dated snapshot, not live availability or outcome data. The older overview provides background; individual classification requires the applicable Japanese rules and the exact plan. Sources checked on 4 November 2026.

Source Scope and limitations Checked
[1] Japanese Law Translation, Act on the Safety of Regenerative Medicine Article 2: classes and scope; Articles 3–5: standards and advance plans; Articles 7–11: committees and Class I waiting period; Article 14: explanation and consent. English translation; consult applicable Japanese rules for an individual classification. 4 November 2026
[2] MHLW, implementation-status snapshot as of 30 June 2026 Section (3): 6,743 treatment plans (8 Class I, 2,463 Class II, 4,272 Class III); 85 research plans separately. Japan; plan counts, not outcomes. 4 November 2026
[3] PMDA-hosted MHLW overview of the safety law Historical system overview: somatic-cell examples; cells and administration considered together; specially certified committees for Classes I and II. Background only, not a current classification algorithm. 4 November 2026
[4] PMDA, Regenerative Medical Products Separate approved-product information and review-report navigation. No product total inferred. 4 November 2026
[5] MHLW, regenerative medicine and gene-therapy framework Current policy hub and updated notices; not evidence of clinic-treatment efficacy. 4 November 2026
[6] MHLW, information on regenerative medicine providers Links to public provision-plan lists for Classes I, II and III; check actual records and available attachments. 4 November 2026
[7] MHLW, Japan Registry of Clinical Trials Research records, status and any posted results. Registration is not proof of efficacy. 4 November 2026
[8] MHLW, e-Saiseiiryo Filing and public-plan portal; records primarily in Japanese. 4 November 2026